SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	Ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5; CD39L4); protein kinase B (PKB; Akt)	*In vitro* and mouse studies suggest that inhibition of ENTPD5 could help treat prostate cancer. In human prostate cancer cell lines and primary prostate tumors, greater ENTPD5 expression correlated with higher levels of oncogenic activated Akt than those in normal cells and tissues. In a human prostate cancer cell line, *ENTPD5* knockdown decreased cell viability compared with vehicle control. In mice with xenograft prostate tumors, *ENTPD5* knockdown reduced tumor growth compared with vehicle control. Next steps could include investigating the role of ENTPD5 in other cancers. ***SciBX*** **3(47); doi:10.1038/scibx.2010.1411** **Published online Dec. 9, 2010**	Patent and licensing status unavailable	Fang, M. *et al. Cell*; published online Nov. 12, 2010; doi:10.1016/j.cell.2010.10.010 **Contact:** Xiaodong Wang, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas e-mail: xiaodong.wang@utsouthwestern.edu